Life and death on the posterior capsule

Article

The UK?s Professor John Marshall looks at the evolution of excimer delivery systems.

Whilst posterior capsule opacification (PCO) rates had been dramatically reduced in the past few years thanks to IOL design and development there was still a great deal of work to be done in addressing what remains the common complication following implant and cataract surgery, according to Dr David Spalton who delivered the Ridley Medal Lecture at ESCRS in Paris.

Life and death on the posterior capsule was the theme of his talk and he addressed the strides made since Harold Ridley implanted the very first IOL in 1949 from realizing that PCO was not an inevitable result of the procedure, that square edge profiles made a difference in prevention and that resistance was best offered by a 360 degree square edged barrier on the IOL so that lens ephithelial cells could not migrate across the optic-haptic onto the posterior capsule.

Dr Spalton also acknowledged that as the trend towards microincision surgery increased manufacturers were concentrating on developing thinner-edged lenses to insert in a small incision but this was at the expense of incorporating a 360 degree square edged barrier. He predicted that this trend would not be reversible and that the answer to further reduction in PCO rates would emerge from elsewhere. Research to achieve this currently includes isolation of the lens epithelial cells, a means of destroying them completely or removing them by means of an open bag device.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.